At the preclinical stage, as dose-effect responses have emerged in the current research on IL-37 in type 2 diabetes, it is crucial to comprehensively evaluate the dose-response relationship and safety of recombinant IL-37 under various pathological conditions in the future. The gene discussed is IL37; the disease is type 2 diabetes mellitus.